Oragenics
OGEN
17 hedge funds and large institutions have $6.22M invested in Oragenics in 2020 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 5 closing their positions.
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
56% more capital invested
Capital invested by funds: $3.98M → $6.22M (+$2.23M)
42% more funds holding
Funds holding: 12 → 17 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$137K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$105K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$76.8K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$55.1K |
| 5 |
IWC
Integrated Wealth Concepts
Waltham,
Massachusetts
|
+$44.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$93.5K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$22K |
| 3 |
Bank of New York Mellon
New York
|
-$12K |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$5.9K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$4K |
OGEN Hedge Fund Activity: Q2 2020 in Review
17 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Oragenics (OGEN) for Q2 2020, worth a combined $6.22M — up 56% from $3.98M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new OGEN positions and 5 closed out — a net gain of 5 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $137K. The largest seller was Barclays, exiting entirely with an estimated $93.5K sold.
- 17 institutional investors held Oragenics (OGEN) as of Q2 2020, up from 12 in Q1 2020.
- Funds reported $6.22M of Oragenics stock for Q2 2020, up 56% quarter-over-quarter.
- 10 funds opened new Oragenics positions in Q2 2020 and 5 closed out, a net change of +5 holders.
- The largest Oragenics buyer in Q2 2020 was Renaissance Technologies, an estimated $137K added.
- The largest Oragenics seller in Q2 2020 was Barclays, an estimated $93.5K sold.
Based on aggregated 13F filings for Q2 2020.